|
Aug 9
|
Eli Lilly (LLY) Partners With Senderra For Innovative Digital Patient Care Solution
|
|
Aug 9
|
Apple notches best week in years; Trump shakes Fed leadership: This Week in markets
|
|
Aug 8
|
Why Novo Nordisk Stock Flew Higher on Friday
|
|
Aug 8
|
Why Eli Lilly Stock Sank 18% This Week
|
|
Aug 8
|
GLP-1 race heats up: Where Eli Lilly stands after weak trial data
|
|
Aug 8
|
S&P 500 Advances on Week Amid Gains in Information Technology, Consumer Discretionary
|
|
Aug 8
|
Investing.com’s stocks of the week
|
|
Aug 8
|
Eli Lilly (LLY) Sees Revenue Surge With Innovative Treatments And Raised Earnings Guidance
|
|
Aug 8
|
This Unusually Active Wayfair Put Option Explains a Lot About the Current Markets
|
|
Aug 8
|
Did Eli Lilly Stock Just Have Its Novo Nordisk Moment?
|
|
Aug 8
|
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
|
|
Aug 8
|
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
|
|
Aug 8
|
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
|
|
Aug 8
|
Stock Market News for Aug 8, 2025
|
|
Aug 8
|
Does This $856 Million Investment Make Eli Lilly Stock a Buy?
|
|
Aug 8
|
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
|
|
Aug 8
|
Elevating Patient Care: Senderra Specialty Pharmacy Adds EBGLYSS™ (lebrikizumab-lbkz), Lilly's First-Line Biologic Treatment for Moderate-to-Severe Atopic Dermatitis, to SenderraCare+ for a Streamlined, Empowering Digital Patient Experience
|
|
Aug 8
|
CATL, Novo Nordisk, SoftBank: Global Stocks in Focus
|
|
Aug 8
|
Morning Bid: Trump Fed forms, Tech hits high
|
|
Aug 5
|
Pfizer Lifts Profit View as Cuts Offset Flat Sales Outlook
|